Twist, Centogene to develop rare disease assay kits

By The Science Advisory Board staff writers

October 7, 2021 -- Twist Bioscience and Centogene have signed a contract to collaborate on the development and commercialization of custom assay kits for rare diseases.

The kits will be designed to make genetic testing more accessible to patients and add to the understanding of rare diseases. Their collaboration aims to augment the bio databank on rare diseases and may contribute to the discovery and development of new therapies to treat these diseases in the future, the companies said.

Twist, DeepCDR collaborate on antibody libraries
Twist Bioscience announced it is collaborating with DeepCDR to apply deep-learning algorithms to Twist's antibody discovery and optimization capabilities.
Twist inks collaboration deal with Adicet Bio
Twist Bioscience and Adicet Bio will collaborate on the discovery and development of gamma delta T-cell cancer therapies.
Boehringer, Twist to collaborate on antibody discovery
Boehringer Ingelheim and Twist Bioscience have entered a research collaboration to discover therapeutic antibodies against multiple targets.
Twist reports revenue increases for Q3
Twist Bioscience reported revenue increases for the third quarter of fiscal 2021, which ended June 30.
Twist incorporates Molcure AI into antibody discovery efforts
Twist Bioscience announced that it has used Molcure's artificial intelligence (AI) technology to generate new cancer antibodies.

Copyright © 2021 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter